Octreotide long-acting: Brand change

Brand change Active

The funded brand of the 10mg and 20mg octreotide long-acting is temporarily changing from Octreotide Depot Teva to the previously funded brand, Sandostatin LAR.

11 September 2023 Supply update

Teva are now out of stock of the 20 mg presentation (Pharmacode 2615339). Novartis' Sandostatin LAR brand (2150840) is available to order from wholesalers.

Affected product

Chemical: Octreotide long-acting
Brand: Octreotide Depot Teva

  • Presentation: Inj depot 10 mg prefilled syringe
  • Pharmacode: 2615320
  • Likely to go out of stock: December 23 - January 24 
  • Presentation: Inj depot 20 mg prefilled syringe
  • Pharmacode:
  • Out of stock: as at 11 September 2023

The 30 mg presentation (pharmacode 2615347) is unaffected by this issue.

Schedule listings for octreotide long-acting(external link)

Alternative product

This supply issue means that anyone using either the 20 mg or 10 mg strength will need to switch temporarily to Sandostatin LAR. Patients who are prescribed the 30 mg strength will remain on the Octreotide Depot Teva brand.

Sandostatin LAR is the previously funded brand.

  • Octreotide (Sandostatin LAR) inj 10 mg prefilled syringe
  • Pharmacode: 2150832
  • Price: $1,152
  • Pack size: 1
  • Listing date: 1 September 2023
  • Available to order from: Mid-November 2023
  • Octreotide (Sandostatin LAR) inj 20 mg prefilled syringe
  • Pharmacode: 2150840
  • Price: $1,539
  • Pack size: 1
  • Listing date: 1 September 2023
  • Available to order: now

Key dates

Date 10 mg strength 20 mg strength
1 September 2023

Sandostatin brand listed in the Schedule

 Sandostatin brand listed in the Schedule
early September 2023 n/a

Sandostatin brand available from wholesalers

Octreotide Depot Teva brand out of stock 
Mid-November 2023 Sandostatin LAR brand available to order n/a
December 2023-January 2024

Octreotide Depot Teva brand likely to run out

 n/a

Early to mid-2024

 Octreotide Depot Teva brand expected to be resupplied Octreotide Depot Teva brand expected to be resupplied

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is. 

Sign up to our email list for regular emails about supply issues and more(external link)

Notice first published: 9 August 2023